PU.1 is a unique regulatory protein required for the generation of both the innate and the adaptive immune system. It functions exclusively in a cellintrinsic manner to control the development of granulocytes, macrophages, and B and T lymphocytes. We demonstrate that mutation of the PU.1 gene causes a severe reduction in myeloid (granulocyte/macrophage) progenitors. PU.1 -/-myeloid progenitors can proliferate in vitro in response to the multilineage cytokines interleukin-3 (IL-3), IL-6 and stem cell factor but are unresponsive to the myeloid-specific cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF and M-CSF. The failure of PU.1 -/-progenitors to respond to G-CSF is bypassed by transient signaling with IL-3. In the presence of IL-3 and G-CSF, PU.1 -/-progenitors can differentiate into granulocytic precursors containing myeloperoxidase-positive granules. Thus PU.1 is not essential for specification of granulocytic precursors, but is required for their further differentiation. The failure of PU.1 -/-progenitors to respond to M-CSF is due to lack of c-fms gene transcription. Transduction of c-fms into PU.1 -/-myeloid progenitors bypasses the block to M-CSFdependent proliferation but does not induce detectable macrophage differentiation. Therefore, PU.1 appears to be essential for specification of monocytic precursors. Importantly, retroviral transduction of PU.1 into mutant progenitors restores responsiveness to myeloid-specific cytokines and development of mature granulocytes and macrophages. Thus PU.1 controls myelopoiesis by regulating both proliferation and differentiation pathways.
Introduction
Hematopoiesis can be viewed as a patterning process in which a self-renewing, pluripotent stem cell (HSC) gives rise through a series of cell divisions to the eight major cell types of the blood. During its differentiation, the HSC appears to generate a hierarchical array of developmental intermediates, consisting of multipotent and lineage-committed progenitors. The latter cells give rise
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© Oxford University Press to erythrocytes, megakaryocytes, mast cells, granulocytes (e.g. neutrophils), macrophages, and B and T lymphocytes. Progression through the hematopoietic developmental cascade involves tightly controlled patterns of gene expression that are orchestrated by a complex set of transcription factors. Gene targeting in mice has been used to examine the functions of these transcription factors during hematopoiesis (reviewed in Shivdasani and Orkin, 1996) . Mutations in genes encoding these transcription factors, e.g. GATA-1, c-myb, PU.1, Ikaros, E2A, EBF and NF-E2, cause either multilineage or single lineage developmental defects in the hematopoietic system. A central issue to be resolved for many of these transcription factors is whether they regulate development of specific hematopoietic lineages by controlling the specification of progenitors or by regulating their survival and proliferation. Of course, these developmental functions are not mutually exclusive.
The transcription factor PU.1 is a tissue-specific etsfamily member that is expressed in various lineages of the hematopoietic system (Klemsz et al., 1990; Hromas et al., 1993) . It is encoded by the proto-oncogene Spi-1, whose deregulated expression caused by insertion of the spleen focus-forming provirus leads to erythroleukemias in the mouse (Moreau-Gachelin et al., 1988) . Numerous presumptive target genes have been identified for PU.1 in granulocytes, macrophages and B lymphocytes (reviewed in Moreau-Gachelin, 1994; Tenen et al., 1997) . Gene targeting studies have demonstrated that PU.1 is required for the development of both myeloid (granulocyte, macrophage) and lymphoid (B, T) lineages McKercher et al., 1996) . The targeted PU.1 allele generated by Scott et al. (1994) results in embryonic lethality by day 16-18 of gestation and represents a null mutation (Scott et al., 1997) . Fetal liver cells derived from the PU.1 -/-embryos fail to generate macrophage or granulocyte colonies or differentiate into B cells in vitro (Scott et al., 1997) . The defect in development of PU.1 -/-hematopoietic progenitors is cell-intrinsic, since these progenitors do not contribute to the lymphoid or myeloid lineages in either embryonic or bone marrow chimeras (Scott et al., 1997) . RT-PCR analysis of embryoid bodies generated by differentiation of PU.1 -/-embryonic stem (ES) cells indicates that some early myeloid genes can be expressed in the absence of PU.1, but expression of late myeloid genes is blocked (Olson et al., 1995) . However, it remains to be determined whether myeloid progenitors are generated in vivo in the absence of PU.1, and, if so, whether they are capable of proliferating in response to myeloid-specific cytokines. The latter issue is underscored by the presence of functional PU.1-binding sites in the promoters of genes encoding the myeloidspecific cytokine receptor subunits, granulocyte-macrophage colony-stimulating factor receptor α (GM-CSFRα) (Hohaus et al., 1995) , c-Fms (Reddy et al., 1994; Zhang et al., 1994) and granulocyte colony-stimulating factor receptor (G-CSFR) (Smith et al., 1996) .
GM-CSF, G-CSF and macrophage colony-stimulating factor (M-CSF) represent a set of myeloid-specific cytokines that have been shown to be important for development of granulocytes and macrophages (reviewed in Metcalf, 1995) . GM-CSF stimulates the survival, proliferation and differentiation of bipotent granulocytemacrophage progenitors as well as unipotent macrophage or granulocyte progenitors (Metcalf et al., 1986) . GM-CSF acts through a heterodimeric receptor consisting of a cytokine-specific α-chain (GM-CSFRα) and a common β-chain (GM-CSFRβ c ) which is shared with the interleukin-3 (IL-3) and IL-5 receptors (Gorman et al., 1990; Park et al., 1992) . Despite the potent activity of GM-CSF in vitro, targeted mutations of genes encoding this cytokine or its receptor (GM-CSFRβ c ) do not disrupt hematopoieisis in vivo (Dranoff et al., 1994; Stanley et al., 1994; Nishinakamura et al., 1995) . G-CSF stimulates survival, proliferation and maturation of granulocytic progenitors (Suda et al., 1987) . G-CSF acts through a single subunit receptor (the G-CSFR) which does not possess intrinsic kinase activity (Fukunaga et al., 1990) . In contrast to mutation of GM-CSF, targeted mutation of G-CSF or its receptor causes a selective and profound reduction in the number of circulating granulocytes in mice (Lieshke et al., 1994; Liu et al., 1996) . Finally, M-CSF stimulates survival, proliferation and maturation of committed monocytic progenitors (Stanley, 1985) . M-CSF acts through a single subunit receptor tyrosine kinase, also known as the proto-oncogene c-fms (Sherr et al., 1985; reviewed in Sherr, 1990) . M-CSF is required for development of macrophages and monocyte-derived lineages such as osteoclasts in mice, since a mutation in the M-CSF gene (op) results in greatly reduced numbers of tissue macrophages and osteopetrosis (Yoshida et al., 1990) .
Given the multilineage defects induced by the PU.1 mutation, it is possible that PU.1 also regulates myelopoiesis by controlling the proliferation/survival of multipotential hematopoietic progenitors. The cytokines IL-3, IL-6 and stem cell factor (SCF) have been shown to act on stem cells and multipotential progenitors (reviewed in Watowich et al., 1996) . IL-3 has the broadest specificity of any known cytokine, as it stimulates survival, proliferation and differentiation of HSCs and progenitor cells of all known hematopoietic lineages (reviewed in Schrader, 1994) . IL-3 acts through a heterodimeric receptor consisting of an IL-3-specific α-chain (IL-3Rα) and either an IL-3-specific β-chain (β IL-3 ) or a common beta chain (β c ) shared with the GM-CSF and IL-5 receptors. Targeted mutation of IL-3 or the IL-3 receptors reveals that IL-3 is not required for steady-state hematopoiesis, but is needed for proliferation of mast cells during parasitic infections (Nishinakamura et al., 1996; Lantz et al., 1998) . IL-6 stimulates survival, proliferation and differentiation of hematopoietic stem cells, and at high concentrations can induce proliferation of committed granulocytic progenitors (reviewed in Kishimoto, 1989; Liu et al., 1996) . IL-6 binds to a heterodimeric receptor consisting of an IL-6-specific α subunit and a signaling subunit, gp130, which is shared with several other related cytokine receptors (Taga et al., 1989) . Targeted mutation of IL-6 causes a selective reduction in granulocytic progenitors (Liu et al., 1997) . SCF promotes survival, proliferation and differentiation of stem cells and progenitors of multiple lineages (reviewed in Lyman and Jacobsen, 1998) . SCF binds to c-Kit, a single subunit receptor with tyrosine kinase activity (Williams et al., 1990) . The white-spotting (W) or steel (Sl) mutations in mice represent defects in c-kit or the SCF gene, respectively, and cause multilineage hematopoietic defects (reviewed in Witte, 1990) .
We have analyzed the effect of the PU.1 mutation on the fate of myeloid progenitors by performing clonogenic assays in the presence of multilineage or myeloid-specific cytokines. We find that the PU.1 mutation severely reduces but does not eliminate myeloid progenitors. These progenitors are capable of responding to the multilineage cytokines IL-3, IL-6 and SCF, but not to the myeloidspecific cytokines GM-CSF, G-CSF and M-CSF. The inability of PU.1 -/-myeloid progenitors to respond to G-CSF or M-CSF can be bypassed by transient culture in IL-3 or by retroviral transduction of c-fms, respectively. However, after bypass of the block to proliferation, PU.1 -/-progenitors undergo limited granulocytic differentiation but no detectable monocytic differentiation. Differentiation of PU.1 -/-myeloid progenitors into neutrophils and macrophages is restored by retroviral transduction with PU.1 cDNA. Therefore, PU.1 controls both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors.
Results
PU.1 -/-hematopoietic progenitors proliferate in response to IL-3, IL-6 and SCF Previous studies have established that PU.1 -/-fetal liver hematopoietic progenitors can give rise to normal numbers of erythroid and megakaryocytic colonies but fail to produce macrophage (M), granulocyte (G), mixed granulocyte-macrophage (GM) or mixed granulocyteerythrocyte-megakaryocyte-macrophage (GEMM) colonies in response to conditioned medium from pokeweed mitogen-stimulated spleen cells (Scott et al., , 1997 . To characterize the effect of the PU.1 mutation on multipotential hematopoietic progenitors, we analyzed the ability of such progenitors to respond to the multilineage cytokines IL-3, IL-6 and SCF. Among these cytokines, IL-3 has been shown potently to induce colony formation by multipotential progenitors (Schrader, 1994) . IL-6 and SCF stimulate colony formation by such progenitors weakly on their own but function synergistically with IL-3 (Bodine et al., 1992; Miura et al., 1993) . To examine the response of PU.1 -/-hematopoietic progenitors to IL-3, we initially enriched for multipotential cells using a lineage depletion protocol. Cells positive for lineage (Lin) markers (CD4, CD8, CD3ε, CD5, B220, Gr-1, Ter119) were depleted using magnetic beads (see Materials and methods). This protocol when used on wild-type or PU.1 ϩ/-fetal liver hematopoietic cells resulted in a depletion of 80-90% of the Lin ϩ cells, producing a population that was Ͼ90% c-Kit ϩ . Importantly, PU.1 -/-Lin -hematopoietic progenitors were also 80-90% c-Kit ϩ and expressed the receptor at levels comparable with their heterozygous counterparts (data not shown).
We tested the response of lineage-depleted (Lin -) day Figure 1 , left panel), while mast cells were detected at a lower frequency (data not shown).
In contrast, PU.1 -/-progenitors gave rise to colonies of cells with immature nuclear and cytoplasmic morphology ( Figure 1 , right panel), suggesting that these cells are myeloid progenitors that are unable to differentiate in the absence of PU.1. We tested whether IL-6 and SCF could synergize with IL-3 to promote survival and proliferation of IL-3-responsive PU.1 -/-progenitors. Table I shows that IL-6 and SCF functioned synergistically with IL-3 to promote survival and proliferation of PU.1 -/-progenitors. In the IL-3 ϩ IL-6 ϩ SCF condition, 2190 colonies were obtained compared with 42 colonies before cytokine stimulation, indicating that the progenitors had doubled approximately six times, or once every 16 h. It should be noted that after stimulation with IL-3, IL-6 and SCF, the 4458 frequency of IL-3-responsive progenitors was equivalent in the PU.1 -/-and ϩ/-populations. However, after cytokine stimulation, PU.1 -/-IL-3-dependent progenitors still maintained an immature morphology and did not differentiate into macrophages or granulocytes (data not shown). These results show that the PU.1 mutation severely reduces the frequency of myeloid progenitors but does not affect their ability to proliferate in response to the multilineage cytokines IL-3, IL-6 and SCF.
PU.1 -/-myeloid progenitors express certain myeloid-restricted genes
RT-PCR was used to detect transcripts of myeloid genes in PU.1 ϩ/-and -/-Lin -progenitors before and after stimulation with IL-3, IL-6 and SCF. Analysis of the genes for myeloid cytokine receptor subunits (G-CSFR, GM-CSFRα, GM-CSFRβ c , c-Fms) revealed three types of differences between PU.1 ϩ/-and -/-progenitors ( Figure 2 ). Transcripts for G-CSFR and GM-CSFRα were less abundant in the PU.1 -/-progenitors and showed an increase after cytokine stimulation. In contrast, GM-CSFRβ c transcripts were barely detectable in PU.1 -/-progenitors before cytokine stimulation and showed a very large increase after culture with IL-3, IL-6 and SCF. Finally, c-fms transcripts were not detectable in PU.1 -/-progenitors either before or after cytokine stimulation.
In addition to subunits of the myeloid cytokine receptors, we analyzed expression of various myeloid structural genes. Myeloperoxidase (MPO) RNA is typically highly expressed in early myeloid cells and downregulated during neutrophil development (Lubbert et al., 1991; Nuchprayoon et al., 1994) . CD16 (FcγRIII, Ravetch et al., 1986; Feinman et al., 1994) , CD32 (FcγRII, Hogarth et al., 1987) and CD64 (FcγRI, Sears et al., 1990; Eichbaum et al., 1994; Perez et al., 1994) are IgG Fc receptors expressed on myeloid cells. CD11b is expressed on macrophages and granulocytes and functions as an adhesion molecule (Pytela, 1988; Pahl et al., 1993) . Finally, the macrophage scavenger receptor (SR) functions in macrophage adhesion to pathogens, and its expression is restricted to macrophages (Moulton et al., 1994; Suzuki These results strongly suggest that PU.1 -/-myeloid progenitors can express certain myeloid genes such as those for G-CSFR, GM-CSFRα, GM-CSFRβ c , MPO and CD16. Reduced transcript levels for these genes in PU.1 -/-progenitors is probably due to a lower frequency of such progenitors in the Lin -population as revealed by the IL-3 colony-forming assay. Upon cytokine stimulation, such PU.1 -/-myeloid progenitors are able to proliferate, giving rise to increased transcript levels for the aforementioned genes.
PU.1 is required to induce G-CSF responsiveness but can be bypassed by stimulating mutant progenitors with IL-3
Analysis of myeloid cytokine receptor subunit genes by RT-PCR ( Figure 2 ) suggested that PU.1 -/-myeloid progenitors may respond to G-CSF and GM-CSF but not to M-CSF. We therefore tested the responses of PU.1 -/-myeloid progenitors to individual cytokines before and after stimulation with the multilineage cytokines IL-3, IL-6 and SCF. Intriguingly, freshly isolated PU.1 -/-myeloid progenitors did not form colonies in G-CSF but were able to do so after cytokine stimulation ( Table Table II II). Although comparable numbers of G-CSF-dependent colonies were observed for PU.1 ϩ/-and -/-progenitors after cytokine stimulation, the mutant colonies were consistently smaller and contained morphologically immature cells compared with the segmented neutrophils that comprised PU.1 ϩ/-colonies ( Figure 3 , left and middle panels). To determine which of the three multilineage cytokines induced G-CSF responsiveness in PU.1 -/-myeloid progenitors, we incubated these cells with individual factors or combinations of factors prior to plating in G-CSF (Table III) . Stimulation with IL-3 or IL-6 ϩ SCF was sufficient to induce G-CSF reponsiveness in PU.1 -/-progenitors. The combination of IL-3 ϩ IL-6 was most potent at inducing colony formation by mutant progenitors in G-CSF. It should be noted that prior stimulation of PU.1 -/-progenitors with IL-3 ϩ IL-6 ϩ SCF for as little as 24 h could induce the G-CSFresponsive state (data not shown). Thus, transient signaling by IL-3 or a combination of multilineage cytokines bypasses the requirement for PU.1 in the generation of G-CSFresponsive myeloid progenitors.
PU.1 can restore G-CSF-dependent differentiation of granulocytes upon transduction into mutant myeloid progenitors
In order to examine the ability of PU.1 to restore differentiation of neutrophils from mutant myeloid progenitors, we constructed a retroviral vector based on murine stem cell virus (MSCV). This vector has been shown to express transduced genes efficiently in ES cells and HSCs and their progenitors (Beck-Engeser et al., 1991; Hawley et al., 1994) . We modified the MSCV-pac vector by replacement of the puromycin acetylase gene with the cDNA for enhanced green fluorescent protein (EGFP) (Cormack et al., 1996) . PU.1 ϩ/-and -/-Lin -fetal liver progenitors were infected with high-titer, cell-free MSCV-EGFP or MSCV-EGFP-PU.1 retrovirus (see Materials and methods) after stimulation with IL-3 ϩ IL-6 ϩ SCF (Luskey et al., 1992) . 2ϫ10 4 Lin -PU.1 -/-progenitors were stimulated for 96 h in the indicated combinations of 20 ng/ml IL-3, 10 ng/ml IL-6 or 100 ng/ml SCF, washed three times and plated in methylcellulose containing 10 ng/ml G-CSF. G-CSF-dependent colonies were scored after 7 days.
PU.1 promotes G-CSF-dependent proliferation of myeloid progenitors as well as their differentiation into neutrophils.
PU.1 is not essential for generation of granulocytic precursors but is required for their differentiation As described above, PU.1 -/-progenitors are capable of extensive proliferation in response to IL-3 and can be induced to undergo limited proliferation in G-CSF. To characterize G-CSF-responsive PU.1 -/-myeloid progenitors further, we attempted to expand such cells using a combination of G-CSF and IL-3. PU.1 ϩ/-or -/-progenitors which had been stimulated with IL-3, IL-6 and SCF were washed and cultured in G-CSF alone. After 7 days, surviving cells were cultured in a combination of G-CSF ϩ IL-3. PU.1 ϩ/-progenitors cultured in G-CSF for 7 days differentiated into neutrophils and subsequently failed to proliferate in G-CSF ϩ IL-3. In contrast, PU.1 -/-progenitors that survived selection in G-CSF responded vigorously to G-CSF ϩ IL-3. These cells could be maintained as cell lines. PU.1 -/-cell lines maintained in G-CSF ϩ IL-3 were analyzed by flow cytometry. These cells do not express B220, Thy-1 or CD11b ( Figure 4A and data not shown). However, the majority of the cells express CD18, the β 2 -integrin partner of CD11b (Kaufmann et al., 1991) , and Gr-1, a marker restricted to developing and mature granulocytes (Hestdal et al., 1991) . The cells also express c-Kit and varying levels of the β IL-3 and β c subunits ( Figure  4A ), consistent with their responsiveness to IL-3. The majority of PU.1 -/-cells expanded in G-CSF ϩ IL-3 contain large lobular nuclei and appear to resemble myelocytes; however, rare cells contain segmented nuclei characteristic of neutrophils ( Figure 4B, left panel) . A significant proportion of these cells (25-50%) contain abundant granules that stain positively for MPO or chloroacetate esterase ( Figure 4B, right and middle panel) . Collectively, the fluorescence-activated cell sorting (FACS) and morphological analyses suggest that these cells are granulocytic precursors. Thus, under appropriate conditions, PU.1 -/-myeloid progenitors can differentiate into G-CSF-responsive granulocytic precursors.
PU.1 controls responsiveness to GM-CSF
Previous RT-PCR analysis (Figure 2) suggested that PU.1 -/-myeloid progenitors express GM-CSFR. To determine if PU.1 -/-myeloid progenitors are responsive to GM-CSF, we performed methylcellulose colonyforming assays in the presence of GM-CSF. In contrast to the findings with G-CSF, PU.1 -/-progenitors did not form colonies in response to GM-CSF either before or after stimulation with IL-3 ϩ IL-6 ϩ SCF (data not shown). In order to determine if PU.1 could restore GM-
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CSF responsiveness in PU.1 -/-myeloid progenitors, we infected PU.1 ϩ/-and -/-Lin -fetal liver progenitors with MSCV-EGFP or MSCV-EGFP-PU.1 retrovirus after cytokine stimulation. PU.1 -/-progenitors infected with the control retrovirus (MSCV-EGFP) did not form colonies in GM-CSF (Table IV) . In contrast, PU.1 -/-progenitors infected with the PU.1 retrovirus (MSCV-EGFP-PU.1) formed mixed granulocyte-macrophage, pure macrophage and pure granulocyte colonies. These colonies were greenfluorescent, clearly demonstrating retroviral transduction, were similar in size to PU.1 ϩ/-colonies and contained morphologically normal granulocytes and macrophages ( Figure 5A ). In addition, a fourth type of colony was Cytokine-stimulated PU.1 ϩ/-and -/-progenitors were infected with cell-free MSCV-EGFP or MSCV-EGFP-PU.1 retrovirus and plated in 1 ng/ml GM-CSF. Colony types were scored after 7 days as mixed granulocyte-macrophage (GM), macrophage (M), granulocyte (G) or other. Cellular identities were confirmed by Wright staining. detected which grew to very large size (10 5 cells) and whose morphology was consistent with that of myeloid progenitors (data not shown). Western analysis using an affinity-purified anti-PU.1 antiserum (Scott et al., 1997) showed that PU.1 protein was expressed at comparable levels in PU.1 ϩ/-or PU.1-transduced mutant colonies ( Figure 5B ). The major PU.1 protein product in transduced mutant colonies migrated faster than its counterpart in PU.1 ϩ/-colonies. This electrophoretic difference may be due to varying levels of phosphorylation (reviewed in Tenen et al., 1997) . These results establish that PU.1 controls responsiveness to GM-CSF, and that this defect is not bypassed by IL-3 signaling.
Retroviral transduction of c-fms restores M-CSFdependent proliferation but not differentiation of PU.1 -/-myeloid progenitors into macrophages
As predicted by the RT-PCR analysis, PU.1 ϩ/-but not -/-myeloid progenitors formed colonies in response to M-CSF (data not shown). To test whether retroviral transduction of the c-fms cDNA into PU.1 -/-progenitors is sufficient to restore M-CSF-dependent macrophage development, we infected PU.1 ϩ/-or -/-progenitors with MSCV-EGFP, MSCV-EGFP-PU.1 or the MZen-fms retrovirus (Rohrschneider et al., 1989) , and then plated these cells in methylcellulose containing M-CSF. PU.1 -/-progenitors formed colonies in response to M-CSF after transduction with PU.1 or c-fms cDNA, but not the control construct (Table V) . PU.1-transduced mutant colonies were green-fluorescent, were similar in size to PU.1 ϩ/-colonies and consisted of morphologically normal macrophages ( Figure 6A , upper panels). In contrast, c-fmstransduced colonies were smaller than control colonies and consisted of morphologically undifferentiated cells ( Figure 6B , lower panels). RT-PCR was performed on RNA prepared from PU.1-or c-fms-transduced PU.1 -/-M-CSF-dependent colonies. Retroviral transduction with PU.1 cDNA restored transcription of c-fms as well as the myeloid-specific genes for CD11b, CD32, CD64 and SR ( Figure 6B ). In contrast, retroviral transduction with c-fms cDNA did not restore transcription of these myeloidrestricted genes. These results demonstrate that c-fms transduction is sufficient to restore the M-CSF proliferation defect in PU.1 -/-myeloid progenitors but does not enable such progenitors to differentiate into macrophages. Therefore, PU.1 acts at distinct levels to control the proliferation and differentiation of macrophage progenitors.
Discussion
Myeloid progenitors are generated in the absence of PU.1 In this study, we present strong evidence that myeloid progenitors can be generated in vivo in the absence of the transcription factor PU.1. These mutant progenitors form colonies in response to IL-3, which contain cells with immature myeloid morphology. However, the number of PU.1 -/-IL-3-dependent colonies is reduced~10-fold compared with PU.1 ϩ/-controls. This reduction in the frequency of myeloid progenitors is consistent with our earlier observation that lymphoid-myeloid progenitors expressing the cell surface marker AA4.1 are reduced but not absent in PU.1 -/-fetal liver (Scott et al., 1997) . PU.1 -/-myeloid progenitors proliferate optimally in response to the multilineage cytokines IL-3, IL-6 and SCF, which previously have been shown to stimulate proliferation of stem cells and multipotential progenitors. The ability of PU.1 -/-myeloid progenitors to proliferate in response to these cytokines is consistent with the idea that the fetal stem cell compartment is unimpaired by the PU.1 mutation, an idea proposed earlier based on the relatively normal numbers of erythrocytes and megakaryocytes in PU.1 -/-fetal liver . Two other lines of evidence demonstrate the existence of myeloid progenitors in PU.1 -/-fetal liver. First, the expression of certain myeloid-restricted genes (for G-CSFR, GM-CSFRα, GM-CSFRβ c , CD16 and MPO) could be detected in freshly isolated or cytokine-stimulated PU.1 -/-hematopoietic progenitors. Finally and conclusively, retroviral transduction of PU.1 -/-myeloid progenitors with PU.1 cDNA restored their ability to form macrophage and neutrophil colonies in response to the colony-stimulating factors G-CSF, GM-CSF and M-CSF. In conclusion, PU.1 is not required for the specification of myeloid progenitors in vivo. However, PU.1 -/-myeloid progenitors are reduced in number relative to controls, a finding which is likely to be accounted for by their failure to proliferate in response to myeloid-specific cytokines (see below).
PU.1 controls responsiveness of myeloid progenitors to myeloid-specific cytokines
As discussed above, myeloid progenitors could be detected in PU.1 -/-fetal liver. PU.1 -/-myeloid progenitors did not form colonies in response to the myeloid-specific cytokines G-CSF, GM-CSF and M-CSF. These results were somewhat unexpected based on the RT-PCR analysis, which showed that PU.1 -/-fetal liver cells expressed transcripts for G-CSFR and GM-CSFR but not c-fms (Figure 2 ). In the case of G-CSFR, PU.1 -/-progenitors could be induced to form small colonies in response to G-CSF after transient stimulation with IL-3. The increase in G-CSFR transcript levels detectable by RT-PCR can reasonably be accounted for by IL-3-stimulated proliferation of myeloid progenitors. Thus, IL-3 signaling is not likely to be inducing G-CSFR expression in PU.1 -/-myeloid progenitors. Therefore, the requirement for PU.1 in G-CSF signaling may be due to failed expression of a PU.1-dependent gene encoding a signal transduction molecule that couples to the G-CSFR. According to this scenario, transient signaling with IL-3 would either induce expression of this gene or activate a functional counterpart.
In the case of GM-CSFR, PU.1 -/-myeloid progenitors did not respond to GM-CSF even though both receptor subunits could be detected by RT-PCR. PU.1 -/-progenitors were unresponsive to GM-CSF both before and after cytokine stimulation. It is possible that the levels of GM-CSFRα transcripts detected by RT-PCR are insufficient for adequate receptor expression on the cell surface. In this regard, we note that PU.1 -/-progenitors can express GM-CSFRβ c on the cell surface ( Figure 4A ). Thus, if GM-CSFRα protein is also expressed on the cell surface at levels sufficient for signal transduction, then PU.1 must regulate GM-CSFR signaling by a mechanism distinct from G-CSFR signaling. Transient stimulation of PU.1 -/-progenitors by IL-3 restores G-CSF-but not GM-CSFdependent proliferation.
In the case of c-fms, PU.1 -/-myeloid progenitors do not express detectable transcripts, demonstrating that transcription of the c-fms gene is critically dependent on PU.1. Retroviral transduction of c-fms cDNA is sufficient to restore responsiveness to M-CSF. However, c-fmstransduced colonies were invariably small in size (Ͻ500 cells) as was also the case for G-CSF-dependent PU.1 -/- colonies. The poor proliferative response of c-fms-transduced PU.1 -/-progenitors may also also be due to failed expression of a PU.1-dependent gene encoding a signal transduction component that couples to c-Fms.
In conclusion, PU.1 controls responsiveness of myeloid progenitors to the myeloid-specific cytokines G-CSF, GM-CSF and M-CSF. The results suggest distinct types of signaling defects in these three cytokine receptor systems induced by the PU.1 mutation. Although functional PU.1-binding sites are found in the promoters of genes encoding G-CSFR, GM-CSFRα and c-Fms, our results show that only c-fms gene transcription is critically dependent on PU.1 in myeloid progenitors. Mutational analysis has shown that G-CSF and M-CSF are important for generating normal numbers of neutrophils and macrophages, respectively (Yoshida et al., 1990; Lieshke et al., 1994) . The reduction, but not elimination of myeloid cells by these mutations is probably due to redundancy in cytokine signaling systems. Although crosses of several of these cytokine or cytokine receptor mutations have been generated (reviewed in Lieshke, 1997) , it remains to be determined how myelopoiesis would be affected by the combined loss of G-CSF, GM-CSF and M-CSF signaling systems. We suggest that the combined loss of these signaling systems may entirely account for the severe reduction in myeloid progenitors in PU.1 -/-fetal liver. 
PU.1 -/-myeloid progenitors partially differentiate along the granulocytic pathway in response to G-CSF ⍣ IL-3
As discussed above, transient signaling with IL-3 allowed a limited proliferative response of PU.1 -/-myeloid progenitors to G-CSF. Induction of this response was exploited to select for G-CSF-responsive progenitors in liquid culture, which were then expanded and maintained as cell lines in G-CSF ϩ IL-3. Under these conditions, PU.1 -/-cell lines displayed limited neutrophil differentiation by several criteria. First, expression of the G-CSFR is restricted to neutrophils and their progenitors (reviewed in Nagata and Fukunaga, 1993) . Secondly, these cells express the myeloid-restricted cell surface marker CD18 and the granulocyte-restricted marker Gr-1. Finally, they accumulate granules in their cytoplasm containing chloroacetate esterase and MPO. It should be noted that the majority of these cells are unable to differentiate into neutrophils, as seen by their immature nuclear morphology and expression of c-Kit. Rarely, cells have segmented nuclear morphology characteristic of neutrophils. In conclusion, G-CSF-responsive PU.1 -/-myeloid progenitors can be expanded and maintained as cell lines in G-CSF ϩ IL-3, and show clear evidence of granulocytic differentiation as revealed by several lineage-specific markers. However, these PU.1 -/-granulocytic precursors are unable to differentiate into c-Kit -neutrophils with segmented nuclear morphology. Thus, PU.1 is not required for the specification of granulocytic precursors in vitro. It should be noted that cells expressing Gr-1 or MPO are not detectable in the fetal liver of PU.1 -/-embryos . This is probably due to the severe reduction in myeloid progenitors as well as the inability of such progenitors to respond to G-CSF signaling in vivo.
PU.1 controls monocytic development at distinct levels of proliferation and differentiation
PU.1 -/-myeloid progenitors do not form colonies in response to M-CSF, as predicted by the lack of detectable c-fms transcription. c-fms-transduced PU.1 -/-progenitors respond weakly to M-CSF, forming small colonies of cells which show no overt morphological differentiation and do not express any macrophage-specific genes. In contrast, PU.1-transduced PU.1 -/-progenitors form robust macrophage colonies in which macrophage-specific gene transcripts can be readily detected. Thus, PU.1 regulates macrophage development at the distinct levels of M-CSFdependent proliferation, as well as by controlling the transcription of macrophage-specific structural genes. PU.1 appears to play a more profound role in regulating both the proliferation and differentiation of monocytic compared with granulocytic cells. This is demonstrated by the failure of PU.1 -/-myeloid progenitors developmentally to activate transcription of c-fms and various macrophagespecific structural genes.
Model for distinct functions of PU.1 in regulating granulocyte and macrophage development
The ability to analyze PU.1 -/-hematopoietic progenitors in vitro using recombinant cytokines, and to restore their development by retroviral transduction with PU.1 cDNA, has provided insight into several distinct functions of PU.1 in the generation of granulocytes and macrophages (Figure 7) . First, granulocyte/macrophage progenitors can be generated in the absence of PU.1; however, their numbers are significantly reduced. Although these progenitors readily proliferate in vitro in response to IL-3, IL-6 and SCF, the results suggest a proliferative/survival defect in vivo. Secondly, although PU.1 -/-myeloid progenitors are defective in responding to G-CSF, transient signaling with IL-3 partially bypasses this block. In the presence of G-CSF and IL-3, PU.1 -/-myeloid progenitors differentiate into granulocytic precursors. Thus, PU.1 is not essential for specification of granulocytic precursors. However, it is required for further differentiation of these precursors into mature neutrophils. In contrast to its role in granulocytic development, PU.1 appears to be more critically required for various steps in the macrophage developmental pathway. In its absence, neither M-CSFdependent proliferation nor differentiation are observed. This is due to a failure developmentally to induce transcription of the c-fms gene and various macrophage-specific structural genes. Thus, PU.1 appears to be required for specification of monocytic precursors. These results are consistent with a model for hematopoiesis which invokes a sequential and ordered emergence of lineage fates (Singh, 1996) . According to this model, granulocytic precursors arise in a developmental sequence before monocytic and lymphoid precursors. Thus we speculate that the lineage specification functions of PU.1 may be executed in a multipotential progenitor that can give rise to macrophages and lymphocytes.
Materials and methods

Mouse strains
Male and female PU.1 ϩ/-mice were mated to produce PU.1 ϩ/ϩ, ϩ/-and -/-embryos for these studies. The presence of a vaginal plug on the morning after matings was taken as day 0.5 of gestation. All embryos were genotyped by PCR analysis of genomic DNA using primers detecting the intact PU.1 gene (sense 5Ј-CGG-ATGTGCTTCCCTTATCAAAC-3Ј, antisense 5Ј-TGACTTTCTTCACC-TCGCCTGTC-3Ј) or the neomycin resistance cassette (sense 5Ј-TTT-CGCTTGGTGGTCGAATC-3Ј, antisense 5Ј-GATGGATTGCACGC-AGGTTC-3Ј).
Isolation of fetal hematopoietic progenitors
Day 14.5 PU.1 ϩ/-and -/-embryos were obtained from timed matings as described above. Embryos were phenotyped by FACS analysis for fetal liver CD11b expression as previously described by Scott et al. (1997) . Genotypes were confirmed by PCR analysis. Fetal liver cell suspensions were prepared by repeated passage of tissue through a 25 gauge needle. These cell suspensions were depleted of erythrocytes using a ficoll gradient (Lympholyte-M, Cedarlane Labs). Fetal liver cell suspensions were depleted of lineage-positive (Lin ϩ ) cells by first incubating with biotinylated monoclonal antibodies to CD4, CD5, CD8a, CD3ε, Gr-1, Ter119 and B220 (PharMingen), then incubating with streptavidin magnetic beads and passing through a MiniMACS or VarioMACS column (Miltenyi Biotec). Lineage-depleted hematopoietic progenitors were stimulated for 2-4 days in complete Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal bovine serum (FBS), 5ϫ10 -5 M β-mercaptoethanol, 1 U/ml L-glutamine, 1 U/ml penicillin-streptomycin, 100 ng/ml recombinant murine SCF (Biosource), 20 ng/ml recombinant murine IL-3 (Biosource) and 10 ng/ml recombinant murine IL-6 (R&D Systems).
Establishment of G-CSF-and IL-3-dependent PU.1 -/-cell lines Cell lines were established by culturing PU.1 -/-cytokine-stimulated hematopoietic progenitors as isolated above in complete IMDM medium containing 10 ng/ml recombinant G-CSF (R&D Systems) for 7 days. Surviving cells were washed and maintained in 10 ng/ml G-CSF and 5 ng/ml IL-3 at cell densities between 10 5 and 10 6 cells/ml.
Colony-forming assays
PU.1 ϩ/-or -/-hematopoietic progenitors were plated in 1.5 ml of 0.9% methylcellulose mixture (MethoCult, StemCell Technologies) in 35 mm Petri dishes (Falcon). MethoCult was supplemented with 1% penicillin-streptomycin, 1% L-glutamine, 5ϫ10 -5 M β-mercaptoethanol, and either 10 ng/ml recombinant murine IL-3, 1 ng/ml recombinant 4466 murine GM-CSF (R&D Systems), 10 ng/ml recombinant murine M-CSF (R&D Systems) or 10 ng/ml recombinant murine G-CSF. After 7 days of incubation, colonies were counted and analyzed by Wright staining. Colonies generated by transduction of progenitors with EGFP-encoding retroviruses were examined using a Zeiss Axiovert inverted fluorescent microscope.
Cytochemical analysis
Cells from individual colonies or PU.1 -/-cell lines (up to 10 5 cells) were cytocentrifuged onto glass slides, fixed for 30 s in methanol and examined by Wright stain (Sigma). Chloroacetate esterase or MPO were detected as described (Yam et al., 1971) . Cells were photographed using a Zeiss Axiovert microscrope. MSCV-pac (Hawley et al., 1994) was modified by replacement of the puromycin resistance gene with the gene for EGFP (Cormack et al., 1996) (Clontech). EGFP was amplified by PCR to introduce HindIII and ClaI sites, then directionally ligated into the HindIII and ClaI sites of MSCV-pac to produce MSCV-EGFP. HA-tagged PU.1 cDNA (Brass et al., 1996) was blunt-end ligated into the HpaI site of MSCV-EGFP to produce MSCV-EGFP-PU.1.
Retroviral production
φNX-Eco retroviral packaging cells (Kinsella and Nolan, 1996) were maintained in complete Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS. φNX-Eco cells at Ͼ80% confluence on 15 cm dishes were transiently transfected with 50 μg of DNA using the calcium phosphate method. Transfections were done in the presence of 25 μM chloroquine to increase viral titer as previously described (Pear et al., 1993) . After changing the medium once, retroviral supernatants were collected at 18 and 36 h and pooled. pMZen-fms virus was produced as a supernatant from stably transfected ψ2 packaging cells as described (Rohrschneider et al., 1989) . Retroviral supernatants were concentrated 20-fold using a 500 kDa cut-off filter in a stirred-cell ultrafiltration apparatus (Amicon). Concentrated virus was frozen in aliquots and titered using NIH 3T3 cells.
Infection of fetal hematopoietic progenitors with retroviral constructs
Cell-free retroviral stocks were titered by infection of NIH 3T3 cells for 4 h in the presence of 8 μg/ml polybrene (Sigma), after which the medium was changed. After 2 days to allow retroviral integration and protein expression, FACS analysis for EGFP fluorescence was performed to measure viral titer. For the MZen-fms retrovirus, titer was measured by FACS analysis for the c-Fms extracellular domain as described (Bourette et al., 1997) . Titers of viruses used in this study were Ͼ1ϫ10 7 infectious particles/ml.
Lin -fetal liver progenitors that had been cultured in IL-3, IL-6 and SCF for 2 days were infected by resuspension in high-titer, cell-free retroviral supernatants for 4 h in the presence of 25 μg/ml polybrene. Infected cells were washed three times in complete medium, then cultured for 2 days in complete medium containing IL-3, IL-6 and SCF to allow retroviral integration and expression. Infected cells were washed three times before plating in methylcellulose to assess colonyforming potential.
RT-PCR
Total RNA was prepared from cells using RNAzol B reagent according to the manufacturer's instructions (Tel-Test Inc.). Random-primed cDNA was generated using a first-strand cDNA synthesis kit (Pharmacia). PCR was performed using 2 pM primers, 0.1 mM dNTPs and 0.1 U/ml Taq DNA polymerase (Boehringer Mannheim). Buffer and pH conditions were optimized for each primer pair using a PCR optimization kit (Opti-Prime, Stratagene). PCR was performed using 30 cycles. The following primers were used: G-CSFR, (sense 5Ј-CTCAAACCTAT-CCTGCCTCATG-3Ј, antisense 5Ј-TCCAGGCAGAGATGAGCGAATG-3Ј); GM-CSFRα (sense 5Ј-GAGGTCCACAGGTCAAGGTG-3Ј, antisense 5Ј-GATTGACAGTGGCAGGCTTC-3Ј); GM-CSFRβ c (sense 5Ј-TTTCCATCACAAACGAAGACT-3Ј, antisense 5Ј-AATGAATGAGTA-AGCCATCTT-3Ј); c-fms (sense 5Ј-GCGATGTGTGAGCAATGGCAGT-3Ј, antisense 5Ј-AGACCGTTTTGCGTAAGACCTG-3Ј); MPO (sense 5Ј-ATGCAGTGGGGACAGTTTCTG-3Ј, antisense 5Ј-GTCGTTGTAG-GATCGGTACTG-3Ј); CD16 (sense 5Ј-ATGTTTCAGAATGCACACT-CT-3Ј, antisense 5Ј-CAGAAATCACTCCCAGATCTA-3Ј); CD32 (sense 5Ј-TGCAAAGGAAGTCTAGGAAGG-3Ј, antisense 5Ј-GCAGAAGA-GTCTTGAGTTGGG-3Ј); CD64 (sense 5Ј-ATTCGGAGGTCGCCATT-CTGA-3Ј, antisense 5Ј-CCATCGCTTCTAACTTGCTGA-3Ј); CD11b (sense 5Ј-AAACCACAGTCCCGCAGAGAGC-3Ј, antisense 5Ј-GCCA-GGTCCATCAAGCCATCCA-3Ј); SR (sense 5Ј-GTACTAATACCTG-TTGTTGGA-3Ј, antisense 5Ј-CGTGCGCTTGTTCTTCTTTCA-3Ј); β-actin (sense 5Ј-CCTAAGGCCAACCGTGAAAAG-3Ј, antisense 5Ј-TCTTCATGGTGCTAGGAGCCA-3Ј).
Western blot analysis of PU.1 protein
Proteins from whole cell lysates were resolved by SDS-PAGE and electrotransferred to a supported nitrocellulose membrane (Gibco-BRL). The membrane was incubated with an affinity-purified anti-PU.1 antibody (Scott et al., 1997) . Immunoreactive proteins were detected using HPRTconjugated anti-rabbit antibody and the ECL system (Amersham).
Antibodies/FACS analysis
Flow-cytometric analysis was performed on single-cell suspensions of cells washed in phosphate-buffered saline (PBS) containing 0.05 M EDTA and 0.5% BSA. Cells were stained with fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-conjugated antibodies and analyzed on a FACScan (Becton-Dickinson). Propidium iodide uptake and sense scatter gating for cell size were used to exclude dead cells from analysis. Antimouse monoclonal antibodies used in this study included H129.19 (CD4), 53-6.7 (CD8a), 53-7.3 (CD5), 145-2C11 (CD3ε), C71/16 (CD18), M1/70 (CD11b, Mac-1), RBC-8C5 (Ly-6G, Gr-1), Ter119, RA3-6B2 (B220, CD45R) and 2B8 (c-Kit, CD117), and were used according to the instructions of the supplier (PharMingen). HA (β IL-3 , AIC2A) and HB antibodies (β c , AIC2B) were obtained from Medical and Biological Research Laboratories Co. Ltd (MBL).
